Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 15;11(2):569.
doi: 10.3390/biomedicines11020569.

Novel Therapeutic Targets for Migraine

Areeba Nisar  1 , Zubair Ahmed  2 , Hsiangkuo Yuan  1
Affiliations
Review

Novel Therapeutic Targets for Migraine

Areeba Nisar et al. Biomedicines. .

Abstract

Migraine, a primary headache disorder involving a dysfunctional trigeminal vascular system, remains a major debilitating neurological condition impacting many patients' quality of life. Despite the success of multiple new migraine therapies, not all patients achieve significant clinical benefits. The success of CGRP pathway-targeted therapy highlights the importance of translating the mechanistic understanding toward effective therapy. Ongoing research has identified multiple potential mechanisms in migraine signaling and nociception. In this narrative review, we discuss several potential emerging therapeutic targets, including pituitary adenylate cyclase-activating polypeptide (PACAP), adenosine, δ-opioid receptor (DOR), potassium channels, transient receptor potential ion channels (TRP), and acid-sensing ion channels (ASIC). A better understanding of these mechanisms facilitates the discovery of novel therapeutic targets and provides more treatment options for improved clinical care.

Keywords: Delta opioid receptor; adenosine; migraine; pituitary adenylate cyclase-activating polypeptide; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Dr. Nisar has no conflicts of interest. Dr. Ahmed receives honoraria from Abbvie, Biohaven and Eli Lilly. Within the past 24 months, Dr. Yuan has received funding from NIH (R44NS115460), institutional support for serving as an investigator from Teva and Abbvie, and royalties from Cambridge University Press and MedLink.

Figures

Figure 1
Figure 1
Illustration of several potential therapeutic targets under investigation for migraine management. Adenosine receptors (A1/A2A), Pituitary adenylate cyclase-activating polypeptide (PACAP) receptor, δ-opioid receptor (DOR), calcitonin gene-related peptide (CGRP) receptors are G-protein coupled receptors, whereas Acid-sensing ion channels (ASIC), transient receptor potential channels (TRP), and potassium channels (KATP) are ion channels.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stovner L.J., Hagen K., Linde M., Steiner T.J. The global prevalence of headache: An update, with analysis of the influences of methodological factors on prevalence estimates. J. Headache Pain. 2022;23:34. doi: 10.1186/s10194-022-01402-2. - DOI - PMC - PubMed
    1. GBD Diseases Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9. - DOI - PMC - PubMed
    1. Edvinsson L., Haanes K.A., Warfvinge K., Krause D.N. CGRP as the target of new migraine therapies—Successful translation from bench to clinic. Nat. Rev. Neurol. 2018;14:338–350. doi: 10.1038/s41582-018-0003-1. - DOI - PubMed
    1. Ashina M., Hansen J.M., Do T.P., Melo-Carrillo A., Burstein R., Moskowitz M.A. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019;18:795–804. doi: 10.1016/S1474-4422(19)30185-1. - DOI - PMC - PubMed
    1. Brain S.D., Williams T.J., Tippins J.R., Morris H.R., MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985;313:54–56. doi: 10.1038/313054a0. - DOI - PubMed